Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis

References

• Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–76.
   PubMedGoogle Scholar
• Hafeez F, Tarar AM, Saleem R. Lupus nephritis in children. J Coll Physicians Surg Pak. 2008;18(1):17–21.
   PubMedGoogle Scholar
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991;34(8):945–50.
   PubMedGoogle Scholar
• Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(10):971–80.
   PubMed Web of Science ®Google Scholar
• Cassidy TJ, Petty ER, Laxer MR, Lindsley M. Systemic lupus erythematosus. In: Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier, 2010. p. 314–343.
   Google Scholar
• Pillkington C, Tucker LB, Isenberg DA. Systemic lupus erythematosus. In: Isenberg DA, Miller JJ, editors. Adolescent Rheumatology. London: Martin Dunitz, 1999. P.71–94.
   Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–1809.
   PubMedGoogle Scholar
• Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, Kovalesky A. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr. 1989;114(6):1055–60.
   PubMedGoogle Scholar
• Miyamae T, Nakajima S, Imagawa T, Itou S, Katakura S, Tomono N, et al. Improved maintenance therapy for juvenile lupus nephritis. Effect of introduction of an immunosuppressant in remission maintenance after methylprednisolone pulse therapy. Jap J Rheumatol. 2000;39:829–35 [in Japanese].
   Google Scholar
• Yokota S, Mori M, Miyamae T, Itou S, Imagawa T, Ibe M. Cyclophosphamide pulse therapy for systemic lupus erythematosus. Jap J Pediatr Med. 1998;30:1666–8 [in Japanese].
   Google Scholar
• Kurosawa R, Umebayashi H, Imagawa T, Katakura S, Mori M, Mituda T, et al. Diagnostic Characteristics of 38 children with systemic lupus erythematosus. J Jpn Pediatr Soc. 2006;110:398–405 [in Japanese].
   Google Scholar
• Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol. 1998;12(3):511–27.
   PubMedGoogle Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.
   PubMed Web of Science ®Google Scholar
• Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715–23.
   PubMedGoogle Scholar
• Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J Am Soc Nephrol. 2005;16(4): 1076–84.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95.
   PubMed Web of Science ®Google Scholar
• Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6(9):2192–9.
   PubMedGoogle Scholar
• Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–9.
   PubMedGoogle Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Yap DY, Ma MK, Mok MM, Tang CS, Chan TM. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology. 2013;52(3):480–6.
   PubMedGoogle Scholar
• Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103–12.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
   PubMed Web of Science ®Google Scholar